ELISA/assay

Mouse Alpha Synuclein ELISA Kit

MBS006917

48-Strip-Wells

470 USD

ELISA Kit

Mouse Alpha Synuclein ELISA Kit

[Alpha Synuclein]

[SNCA; Alpha-synuclein; alpha-synuclein; synuclein alpha-140; non A-beta component of AD amyloid; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor]

[SNCA]

[SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP]

SYUA_HUMAN

Mouse

No significant cross-reactivity or interference between this analyte and analogues is observed.

Store all reagents at 2-8 degree C

Samples: Human Body Fluids And Tissue Homogenates. Assay Type: Quantitative Sandwich. Detection Range: 0.625ng/ml-20ng/ml. Sensitivity: 0.1ng/ml.

Intra-assay Precision: Intra-assay CV (%) is less than 15%. Inter-assay Precision: Inter-assay CV (%) is less than 15%. [CV(%) = SD/mean ×100]. All CV% should be compared by concentration, not compared by OD values.

Background/Introduction: This Quantitative Sandwich ELISA kit is for lab reagent/research use only, not for drug, household, therapeutic or diagnostic applications! This kit is intended to be used for determine the level of SNAP25 (hereafter termed "analyte") in undiluted original Human body fluids and tissue homogenates. This kit is NOT suitable for assaying non-biological sources of substances.

49456267

CAG46454.1

P37840

14,460 Da

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; extracellular region; fibril; terminal button; cell cortex; inclusion body; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; synaptic vesicle; platelet alpha granule membrane; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; cell junction; nucleus. Molecular Function: identical protein binding; protein domain specific binding; zinc ion binding; histone binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; beta-tubulin binding; magnesium ion binding; phosphoprotein binding; protein N-terminus binding; calcium ion binding; Hsp70 protein binding; oxidoreductase activity; dynein binding; protein binding; phospholipase binding; copper ion binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding. Biological Process: regulation of acyl-CoA biosynthetic process; positive regulation of apoptosis; adult locomotory behavior; positive regulation of endocytosis; response to lipopolysaccharide; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; fibril organization and biogenesis; synapse organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; mitochondrial membrane organization and biogenesis; negative regulation of norepinephrine uptake; microglial cell activation; negative regulation of caspase activity; negative regulation of transcription from RNA polymerase II promoter; negative regulation of monooxygenase activity; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; receptor internalization; phospholipid metabolic process; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; negative regulation of microtubule polymerization; regulation of glutamate secretion; regulation of macrophage activation; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential. Disease: Parkinson Disease 4, Autosomal Dominant; Dementia, Lewy Body; Parkinson Disease 1, Autosomal Dominant

48-Strip-Wells

470 USD

96-Strip-Wells

680

5x96-Strip-Wells

3100

10x96-Strip-Wells

6095